EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022.
Recent Highlights
- Delivered total revenue of $20.2 million for the first quarter of 2022, representing growth of 8.5% year over year
- Signed a strategic partnership agreement with Vestaron to develop pesticidal peptides using the Company’s Beacon® platform and proprietary high-throughput, functional screening service
- Released an upgrade to the Software Suite for Beacon and Lightning® platforms, enabling customers to gain easier insights and faster throughput operations for antibody discovery, cell line development and cell therapy workflows
- Appointed Siddhartha Kadia as chief executive officer (CEO) and Lucas Vitale as chief human resources officer
“Since joining Berkeley Lights as CEO in early March, I have been working with the team on a strategic analysis of the business to identify key areas to accelerate profitable growth,” said Siddhartha Kadia, Ph.D., CEO of Berkeley Lights. “Over the past eight weeks, I have become even more confident in the breakthrough nature of our technology, our significant opportunities ahead and our ability to create durable value for our shareholders.”
First Quarter 2022 Financial Results
| Three months ended March 31, | ||||||
| (in thousands, except per share data) | 2022 | 2021 | ||||
| (unaudited) | (unaudited) | |||||
| Revenue | $ | 20,206 | $ | 18,628 | ||
| Gross profit | $ | 13,827 | $ | 12,451 | ||
| Gross margin % | 68 | % | 67 | % | ||
| Operating expenses | $ | 35,100 | $ | 27,600 | ||
| Loss from operations | $ | (21,273 | ) | $ | (15,149 | ) |
| Net loss and comprehensive loss | $ | (21,426 | ) | $ | (15,435 | ) |
| Net loss attributable to common stockholders per share, basic and diluted | $ | (0.32 | ) | $ | (0.24 | ) |
| Total stock-based compensation | $ | 5,393 | $ | 4,494 | ||
Webcast and Conference Call Information
Berkeley Lights will host a conference call to discuss the first quarter 2022 financial results after market close on Monday, May 9, 2022 at 1:30 p.m Pacific Time/4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at http://investors.berkeleylights.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect® chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Press Contact
Media@berkeleylights.com
Investor Contact
IR@berkeleylights.com
Berkeley Lights, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data) | |||||||
| Three months ended March 31, | |||||||
| 2022 | 2021 | ||||||
| Revenue: | |||||||
| Product revenue | $ | 9,774 | $ | 13,533 | |||
| Service revenue | 10,432 | 5,095 | |||||
| Total revenue | 20,206 | 18,628 | |||||
| Cost of sales: | |||||||
| Product cost of sales | 2,695 | 3,703 | |||||
| Service cost of sales | 3,684 | 2,474 | |||||
| Total cost of sales | 6,379 | 6,177 | |||||
| Gross profit | 13,827 | 12,451 | |||||
| Operating expenses: | |||||||
| Research and development | 17,573 | 13,027 | |||||
| General and administrative | 11,716 | 8,967 | |||||
| Sales and marketing | 5,811 | 5,606 | |||||
| Total operating expenses | 35,100 | 27,600 | |||||
| Loss from operations | (21,273 | ) | (15,149 | ) | |||
| Other income (expense): | |||||||
| Interest expense | (224 | ) | (354 | ) | |||
| Interest income | 34 | 66 | |||||
| Other income, net | 57 | 19 | |||||
| Loss before income taxes | (21,406 | ) | (15,418 | ) | |||
| Provision for income taxes | 20 | 17 | |||||
| Net loss and comprehensive loss | $ | (21,426 | ) | $ | (15,435 | ) | |
| Net loss attributable to common stockholders per share, basic and diluted | $ | (0.32 | ) | $ | (0.24 | ) | |
| Weighted-average shares used in calculating net loss per share, basic and diluted | 67,697,488 | 65,259,398 | |||||
| Berkeley Lights, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) | |||||||
| Assets | March 31, 2022 | December 31, 2021 | |||||
| (unaudited) | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 164,674 | $ | 178,096 | |||
| Trade accounts receivable | 17,721 | 25,942 | |||||
| Inventory | 15,665 | 14,547 | |||||
| Prepaid expenses and other current assets | 10,304 | 11,985 | |||||
| Total current assets | 208,364 | 230,570 | |||||
| Restricted cash | 270 | 270 | |||||
| Property and equipment, net | 29,913 | 27,992 | |||||
| Operating lease right-of-use assets | 25,325 | 26,060 | |||||
| Other assets | 1,985 | 2,361 | |||||
| Total assets | $ | 265,857 | $ | 287,253 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Trade accounts payable | $ | 8,015 | $ | 8,198 | |||
| Accrued expenses and other current liabilities | 9,916 | 12,425 | |||||
| Deferred revenue | 9,780 | 12,128 | |||||
| Total current liabilities | 27,711 | 32,751 | |||||
| Notes payable | 19,778 | 19,762 | |||||
| Deferred revenue, net of current portion | 1,600 | 2,187 | |||||
| Lease liability, long-term | 23,567 | 24,337 | |||||
| Total liabilities | 72,656 | 79,037 | |||||
| Stockholders’ equity: | |||||||
| Common stock | 4 | 4 | |||||
| Additional paid-in capital | 478,231 | 471,820 | |||||
| Accumulated deficit | (285,034 | ) | (263,608 | ) | |||
| Total stockholders’ equity | 193,201 | 208,216 | |||||
| Total liabilities and stockholders’ equity | $ | 265,857 | $ | 287,253 | |||